The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evolution of Multiple Primary Lung Cancer (Evolution)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04326751
Recruitment Status : Unknown
Verified March 2020 by Peking University People's Hospital.
Recruitment status was:  Not yet recruiting
First Posted : March 30, 2020
Last Update Posted : March 30, 2020
Sponsor:
Collaborator:
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Information provided by (Responsible Party):
Peking University People's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To investigate the evolutionary genomic landscape, explore the genetic tumor heterogeneity and microenvironment of multiple primary lung cancer (MPLC) by using tissue genetic analysis and circulating tumor DNA detection, in order to provide robust evidence for the diagnosis, treatment, and surveillance of MPLC.

Condition or disease
Multiple Primary Lung Cancers Lung Cancer Non Small Cell Lung Cancer

Detailed Description:
Multiple primary lung cancer (MPLC) has become a worldwide problem due to the difficulty in diagnosis, treatment and surveillance. Although exploring tumour clonal heterogeneity and microenvironment can help understand cancer evolution and impact therapeutic outcome, study is still lacking in this field on MPLC. Circulating tumor DNA (ctDNA) are short DNA fragments, which can be obtained conveniently and non-invasively, providing comprehensive views of the tumor as were shed by tumor cells from multiple tumor regions. Therefore, we design a prospective study of patients with surgically treated MPLC, aiming to use ctDNA technique to define the evolutionary landscape of MPLC through inter-tumor and intra-tumor heterogeneity by multi-region sampling and genetic analysis. We will also explore the the microenvironment by RNA sequencing and T cell receptor sequencing. This study may help understand the genetic evolution and microenvironment of MPLC, and provide evidence for the diagnosis, treatment and surveillance of these patients.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Genetic Evolution and Microenvironment of Multiple Primary Lung Cancer
Estimated Study Start Date : January 1, 2021
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Tumor heterogeneity of multiple primary lung cancer [ Time Frame: 3 year ]
    Explore the intra-tumor and inter-tumor genetic heterogeneity by analysis of clonal and subclonal mutations detected by ctDNA.

  2. Microenvironment of multiple primary lung cancer [ Time Frame: 3 year ]
    Using RNA sequencing and T cell receptor (TCR) sequencing to evaluate the microenvironment of each lesion of multiple primary lung cancer, including T cell receptpr clonality ,diversity , evenness, and richness.


Secondary Outcome Measures :
  1. Correlation between ctDNA and clonal variation [ Time Frame: 3 year ]
    Explore the correlation between the detection rate of ctDNA and subclonal mutations of different tumor sites detected by genetic analysis.

  2. Correlation between ctDNA and tumor burden [ Time Frame: 3 year ]
    Explore the correlation between the detection rate of ctDNA and tumor burden.


Biospecimen Retention:   Samples With DNA
Fresh tumor tissue and blood samples were collected from each patient. Time for blood sample collection: 1) Preoperation. 2) The 1st to 3rd day of postoperation.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Histologically confirmed multiple lung cancer patients who will receive surgical therapy
Criteria

Inclusion Criteria:

  • Aged 18 to 80 years

    1. Patients who are clinically diagnosed multiple lung cancers, and undergo surgical treatment.
    2. No history of any malignancy in recent 5 years.
    3. No chemotherapy, radiotherapy or targeted therapy will be performed before surgery.
    4. Surgical removal of at least 2 tumors confirmed to be lung cancer postoperatively by pathologic evaluation.

Exclusion Criteria:

  1. All lesions present as pure ground-glass opacities (GGOs) on CT scans.
  2. Patients who do not undergo R0 resection (including tumors located bilaterally but only unilaterally resected).
  3. Unqualified blood samples.
  4. Unable to comply with the study procedure
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04326751


Contacts
Layout table for location contacts
Contact: Kezhong Chen, M.D. (+86)13488752289 mdkzchen@163.com

Sponsors and Collaborators
Peking University People's Hospital
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Jun Wang, M.D. Peking University People's Hospital Thoracic Surgery Department
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT04326751    
Other Study ID Numbers: PTHO2002
First Posted: March 30, 2020    Key Record Dates
Last Update Posted: March 30, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Peking University People's Hospital:
multiple primary lung cancer
ctDNA
evolution
tumor heterogeneity
microenvironment
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases